Press Release

View printer-friendly version << Back
Juniper Pharmaceuticals to Report First Quarter 2017 Results on May 4, 2017
Conference Call Scheduled for 8:30 a.m. EST

BOSTON, April 28, 2017 /PRNewswire/ -- Juniper Pharmaceuticals (Nasdaq: JNP) ("Juniper" or the "Company"), will hold a conference call on May 4, 2017, to discuss the financial results for the first quarter ended March 31, 2017, as follows:

Date: Thursday, May 4, 2017

Time: 8:30 a.m.

Dial-in numbers: Toll free: (1-866-374-4635) (U.S.), (1-855-669-9657) (Canada), or International: (1-412-902-4218)

Audio webcast (live & archive):, under 'Investors' or click here

The teleconference replay will be available approximately one hour after completion through Thursday, March 11, 2017, at 1-877-344-7529 (U.S.), 1-855-669-9658 (Canada) or 1-412-317-0088 (International). The replay access code is 10105578.

The archived webcast will be available for one year via the aforementioned URLs.

About Juniper Pharmaceuticals

Juniper Pharmaceuticals, Inc. is focused on developing therapeutics that address unmet medical needs in women's health. The Company is advancing a pipeline of proprietary product candidates that leverage its differentiated intravaginal ring technology and when appropriate the 505(b)(2) regulatory pathway. Targeted product development investments are enabled by Juniper's core operating business: the Crinone® (progesterone gel) franchise and Juniper Pharma Services, which provides high-end fee-for-service pharmaceutical development and clinical trials manufacturing to clients. Please visit for more information.

Juniper Pharmaceuticals™ is a trademark of Juniper Pharmaceuticals, Inc., in the U.S. and EU.

Crinone® is a registered trademark of Merck KGaA, Darmstadt, Germany, outside the U.S. and of Allergan, Inc. in the U.S.

Investor Contact:  

Laura Perry 
Argot Partners 
212-600-1902 /

Heather Savelle 
Argot Partners 
212-600-1902 /

To receive Juniper's press releases, SEC filings or calendar alerts by email click here.  
Follow us on

To view the original version on PR Newswire, visit:

SOURCE Juniper Pharmaceuticals, Inc.